Table 2.
Full models of univariate and multivariate-adjusted comparisons between everolimus-based therapy and chemotherapy.
| Characteristic (reference group) | Time to discontinuation | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| Everolimus-based therapy (chemotherapy) unadjusted | 0.36 | (0.27, 0.47) | 0.0000∗ | 0.49 | (0.30, 0.78) | 0.0027∗ | 0.74 | (0.55, 1.01) | 0.0582 |
| Everolimus-based therapy (chemotherapy) adjusted | 0.34 | (0.25, 0.45) | 0.0000∗ | 0.37 | (0.22, 0.63) | 0.0002∗ | 0.70 | (0.50, 0.97) | 0.0326∗ |
| Index therapy line (First line) | |||||||||
| Second line | 1.11 | (0.70, 1.75) | 0.657 | 1.41 | (0.65, 3.05) | 0.380 | 1.26 | (0.77, 2.07) | 0.357 |
| Third line and above | 0.98 | (0.61, 1.56) | 0.918 | 1.07 | (0.46, 2.50) | 0.875 | 1.30 | (0.78, 2.15) | 0.314 |
| Disease status (de novo) | |||||||||
| Recurrent with adjuvant ET | 1.79 | (1.11, 2.89) | 0.018∗ | 1.46 | (0.62, 3.44) | 0.391 | 1.74 | (1.04, 2.93) | 0.036∗ |
| Recurrent without adjuvant ET | 0.63 | (0.34, 1.17) | 0.144 | 0.69 | (0.24, 1.99) | 0.489 | 0.47 | (0.23, 0.98) | 0.043∗ |
| Age at index therapy initiation | 1.00 | (0.97, 1.03) | 0.911 | 1.07 | (1.02, 1.12) | 0.006∗ | 1.01 | (0.98, 1.04) | 0.355 |
| Race (all other races) | |||||||||
| White | 0.68 | (0.51, 0.91) | 0.009∗ | 0.92 | (0.55, 1.52) | 0.739 | 0.77 | (0.56, 1.06) | 0.111 |
| Insurance at mBC diagnosis (neither insurance) | |||||||||
| Private | 1.79 | (0.95, 3.39) | 0.072 | 1.49 | (0.44, 5.08) | 0.525 | 2.36 | (1.07, 5.21) | 0.033∗ |
| Medicare only | 1.83 | (0.91, 3.66) | 0.089 | 1.04 | (0.29, 3.81) | 0.949 | 2.28 | (0.99, 5.25) | 0.053 |
| CCI at index therapy initiation | 1.00 | (0.87, 1.14) | 0.957 | 1.04 | (0.85, 1.28) | 0.713 | 0.95 | (0.82, 1.12) | 0.561 |
| Sites of metastasis at index therapy initiation | |||||||||
| Bone | 1.42 | (1.06, 1.91) | 0.020∗ | 1.28 | (0.76, 2.13) | 0.351 | 1.90 | (1.34, 2.69) | 0.000∗ |
| Visceral | 1.80 | (1.10, 2.96) | 0.020∗ | 1.36 | (0.56, 3.27) | 0.498 | 1.83 | (1.08, 3.12) | 0.025∗ |
| Performance status at index therapy initiation (ECOG 0) | |||||||||
| ECOG 1 | 1.10 | (0.76, 1.60) | 0.600 | 1.78 | (0.83, 3.81) | 0.137 | 1.78 | (1.14, 2.77) | 0.011∗ |
| ECOG 2 | 2.29 | (1.36, 3.86) | 0.002∗ | 4.73 | (1.89, 11.84) | 0.001∗ | 4.13 | (2.31, 7.40) | 0.000∗ |
| ECOG 3 | 20.29 | (7.05, 58.35) | 0.000∗ | 264.30 | (63.54, 1,099.46) | 0.000∗ | 49.13 | (16.74, 144.24) | 0.000∗ |
| None | 1.28 | (0.79, 2.05) | 0.317 | 3.36 | (1.33, 8.49) | 0.011∗ | 2.10 | (1.22, 3.62) | 0.008∗ |
| Previous chemotherapy treatment in mBC setting | 1.39 | (0.92, 2.11) | 0.121 | 2.51 | (1.22, 5.15) | 0.012∗ | 1.21 | (0.76, 1.92) | 0.424 |
| Duration from initiation of last adjuvant ET to mBC diagnosis | 0.99 | (0.99, 1.00) | 0.008∗ | 1.00 | (0.99, 1.01) | 0.961 | 1.00 | (0.99, 1.00) | 0.173 |
∗ P < 0.05.